| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 26, 2026Next | Q3 2026 | — | 1.23 | 5.46 B |
Aug 31, 2026
GEHC vs. HAE: Which Stock Is the Better Value Option?
GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.
CHICAGO, August 31, 2026--GE HealthCare (Nasdaq: GEHC) recently achieved CE Mark for Photonova Spectra,i an advanced photon-counting computed tomography (PCCT) system with the company’s proprietary Deep Silicon™ detector technology. The regulatory milestone expands access and enables clinical adoption of the technology in CE Mark–observing countries and underscores GE HealthCare’s commitment to purposeful, customer-driven innovation in computed tomography (CT).
Aug 28, 2026
GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus systems bring cSound™ imaging with capabilities designed for routine echocardiography, comprehensive cardiac imaging and interventional careGE HealthCare (NASDAQ:GEHC)
Aug 26, 2026
CHICAGO, August 26, 2026--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference:
GE HealthCare Technologies (GEHC) has drawn fresh attention after announcing William K. Grogan as its incoming Chief Financial Officer, effective September 14, 2026, following his finance leadership roles at Xylem and IDEX. For investors watching GE HealthCare Technologies, the recent CFO news comes after a strong 30 day share price return of 22% and a 90 day share price return of 15.7%. However, the year to date share price return is down 10.76%, and the 1 year total shareholder return is...
Aug 24, 2026
GEHC's 11.1% order growth and record $23.9B backlog improve revenue visibility, but PCS execution and inflation remain key constraints.
GEHC's valuation discount and growth in imaging and diagnostics support the case, but PCS weakness, inflation and debt keep execution risks elevated.
GE HealthCare's record backlog, strong Pharmaceutical Diagnostics growth and AI innovation support its growth outlook despite margin pressures.
Aug 19, 2026
BTIG analyst Ryan Zimmerman reiterates GE HealthCare Techs (NASDAQ:GEHC) with a Buy and maintains $79 price target.
Aug 18, 2026
CHICAGO, August 18, 2026--GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today announced the appointment of William (Bill) Grogan as Chief Financial Officer, effective September 14, 2026. Grogan succeeds Jay Saccaro, who, as previously announced, stepped down for an expanded role outside of the medical technology industry. George Newcomb, who is serving as interim Chief Financial Officer, will continue in his role as Controller and Chief Accounting Officer.
GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today announced the appointment of William (Bill) Grogan as Chief Financial Officer, effective September 14, 2026. Grogan succeeds Jay Saccaro,
Aug 14, 2026
Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
GE HealthCare Technologies stock has climbed 19.7% over the past month, yet its valuation checks still lean toward the shares looking cheap rather than stretched. The 19.7% gain over the past month points to a sharp reset in expectations that puts the current pricing under closer scrutiny for new buyers and existing holders. Recent expansion of ultrasound and breast imaging platforms can support expectations for future revenue, while execution risks around new product rollouts may affect how...
Aug 13, 2026
Earlier this month, GE HealthCare introduced the LOGIQ e Xi and LOGIQ e Si laptop ultrasound systems and launched the Invenia ABUS Prime and ABUS StreamVue breast imaging solutions, expanding its AI-enabled and cloud-connected ultrasound portfolio across multiple care settings. These product launches aim to standardize imaging workflows, support remote reading, and address dense-breast screening needs, potentially strengthening GE HealthCare’s position in high-value, technologically advanced...
